My name is [Dean Bradford]. Can you tell me with regards to REO 18, how many patients continue to survive?
Unidentified Company Representative
No, I can’t. That’s – there are certain elements of the study that we do keep confidential and the number of patients that are alive is – but one of them, so – I apologize sort of for not being able to tell you that.
My name is [Darrell Scott]. So rather than telling us how many patients there are alive, can you tell us what the trigger is that you would need to un-blind that particular point?
Unidentified Company Representative
At this time, I can’t disclose what the trigger is, partly, because we’re still working on it. The change of going from 82 patients with a single patient group to a 167 patients representing two patient groups and having actually basically two measurements because you’ve got each of those two patient groups required basically, a complete redefinition of the statistical plan with respect when the endpoint was going to be, going to event driven on those two groups.
And you needed some sense of the progression free survival that you were seeing in the combined groups actually to do that math and that’s what’s going on right now. We’re actually defining that as we go.
New GC to BT: "Don't say ANYTHING about H&N trial. Pretend you never heard about it."
When the Dollar goes to Zero my pantry will be closed to them."
Not too many people want to eat gold. Good luck buying food with gold dust. Let me know how that works out for you.
“We’ve got to make sure that we are not the party of big business, big banks, big Wall Street bailouts, big corporate loopholes, big anything,” Jindal told POLITICO in a 45-minute telephone interview. “We cannot be, we must not be, the party that simply protects the rich so they get to keep their toys.”
“It is no secret we had a number of Republicans damage our brand this year with offensive, bizarre comments — enough of that,” Jindal said. “It’s not going to be the last time anyone says something stoooopid within our party, but it can’t be tolerated within our party. We’ve also had enough of this dumbed-down conservatism. We need to stop being simplistic, we need to trust the intelligence of the American people and we need to stop insulting the intelligence of the voters.”
Yeah for the loss of business now that Obama is ending the Bush slaughter of US troops in Iraq there will be fewer American servicemen to bury.
No of course not,it's Texas. Now Rep. Joe Barton, will apologize to the company for having to clean up the blood.
Do you mean like trying to calculate PFS for the treatment arms, using Hazard Ratios? That would truly be brilliant, in fact revolutionary, since hazard ratios cannot be used to calculate time driven events.
trying to kick the football, only to have Lucy pull it away at the last second. End of q3 for platinum refractory H&N patients? Eastern Europe must have some pretty resilient people, since that is where about 90% of trial participants came from.
As a liberal I would have thought you were smarter than that. What is 5 bucks of cash gonna get you in a company that is burning cash by design and has no revenue (and in ONCY's case no chance of ever having revenue.
You can do your own research but they have very different meanings in various scientific contexts (including clinical trials.) idon't want scout to get too smart. I enjoy him more as a dummmmmeee.
"Within those groups they do not know who got reo and who didn't."
You are correct sir. But that isn't my point. They are blind but they are not st-oo-pid. There are many conclusions and inferences that can drawn from seeing blinded clinical data. In fact, the decision to BREAK the blind is based on BLINDED clinical and statistical results. In addition they got tumor response info by treatment arm in December to add to the mix. Not worth discussing at this point. PFS is useless from a trial standpoint now. But of this much you can be sure, they have mature PFS data as we speak but you ain't gonna see it.
They keep sending guys further down the food chain to these things. First it was BT, then MATT and now the "Johnny come lately" Tuchman. Should be good for a few yucks
"They were documenting tumour responses (you do this before you unblind, of course)"
Huh you cudda fooled me. I thought they were also looking at PFS, since they reported on PFS in September.
"At the time of the analysis, 23 patients of the 80 had not yet progressed but were included for the purposes of analysis. The median evolving progression free survival (PFS) of the 80 patients, which comprises the combined control and test groups, was greater than expected, "
But you are quite right on one point. They are not running the trial they started with and it's not a registration study at this point.
Of course the data on the control and the test arms was reviewed by someone -- and it was BAD so they didn't release it. The data was unblinded ( to someone, prolly the DMC) as part of the trial protocol in order to adjust the enrollment (or suspend for FUTILITY or outrageous success,) which is part of any adaptive trial. They know that the trial FAILED or else they would have announced trhe additional enrollment. End of story. Only after the dreaded "sub group analysis" and frantic sprint to the FDA did they revise the trial into 2 trials (one already DOA). Had they not done so they would have had to announce that NO number of additional trial participants would enable them to reach stat-sig. I don't believe you are a scientist.
your post made me laugh out loud. Tripling down on stoooooopid. A frigggin moron like you equating himself with "pros" is hilarious. I could spit in your cyber face and explain how adaptive and adaptable aren't synonyms but I enjoy watching you make an a-as of yourself among your superiors.. Glad to see you scurry to research and respond to all my posts. (yet still get it wrong) Pukes like you are why I know I'm on the right side of the trade.
I like you it when you double down on stooopididididty. The two terms are not synonymous. But you are far too dense to bother with, other than to point out your errors and let the chips fall where they may.
Oncolytics intends to treat this expanded first stage of the REO 018 clinical trial as a separate SUPPORTIVE study to a (new) planned registration study that will be similar to, and TAKE THE PLACE OF, the original second stage of the REO 018 clinical trial
Please interpret the above copied from the sept press release. People pun-lease.
Cash value is only relevant in companies with a revenue stream. Quoting cash value in development stage pharma co's where it is a certainty that cash will go to zero is senseless. Therefore it will appeal to ONCY longs.